Cidara Therapeutics shares are trading higher after Janssen elected to proceed under its license agreement relating to influenza candidate.
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics' shares are trading higher after Janssen decided to continue under its license agreement related to an influenza candidate.
September 06, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics' stock price is likely to increase in the short term due to Janssen's decision to proceed under its license agreement.
Janssen's decision to continue under its license agreement with Cidara Therapeutics is a positive development for the company. This could lead to increased investor confidence in Cidara, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100